Highest-materiality recent filing
Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track
Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B
Bio-Techne to be acquired by Merck KGaA for $73.00 per share in all-cash deal
Merck KGaA to acquire Bio-Techne (TECH) for $73.00 per share in cash.
Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal
Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.
Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend
Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).
Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out
Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.
Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42
GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.
Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend
Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).
GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.
Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.
Bio-Techne authorizes $500M share repurchase program, replacing prior 2022 authorization
Board authorized up to $500M in common stock repurchases on April 30, 2025.
Bio-Techne ordered to pay former CEO $35.98M over option expiration error
Arbitrator awarded former CEO Charles Kummeth $35.978M for options lost due to administrative error.
Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend
Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.
Bio-Techne grants CFO James Hippel 34,634 RSUs to correct forfeited options
Grant date: October 30, 2024; vesting in three equal annual installments.
Bio-Techne Q1 revenue $289.5M (organic +4%), adj EPS $0.42; declares $0.08 dividend
Q1 revenue $289.5M, up 5% reported (4% organic); GAAP EPS $0.21 vs $0.31; adjusted EPS $0.42 vs $0.41.
Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)
Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.
Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.
Bio-Techne appoints Dr. Judith Klimovsky to board, expands to 11 directors
Dr. Klimovsky appointed independent director effective April 24, 2024; board temporarily expanded to 11 members (10 independent).
Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.
Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024
Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.
Bio-Techne Q1 GAAP EPS $0.31 (down 44% YoY); CEO Kelderman appointed
GAAP diluted EPS $0.31 vs $0.55 prior year; adjusted EPS $0.41 vs $0.45.
Bio-Techne CEO Chuck Kummeth to retire; Kim Kelderman named successor effective Feb 1, 2024
Kelderman becomes COO Nov 1, 2023, then CEO and board member Feb 1, 2024; Kummeth to serve as Senior Advisor until July 1, 2024.
Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51
Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.
Bio-Techne reports Q3 fiscal 2023 results and declares cash dividend; specific figures not available
Press release for quarter ended March 31, 2023 issued May 3, 2023.
Bio-Techne completes $257M investment for 20% stake in Wilson Wolf; future buyout potential $1B
$257M investment gives Bio-Techne 20% ownership of Wilson Wolf Manufacturing.
Bio-Techne invests $257M for 20% of Wilson Wolf; future buyout up to $1B
Wilson Wolf met trailing 12-month EBITDA target of $55M, triggering Bio-Techne's option.
Bio-Techne Q2 FY2023: organic revenue up 4% to $271.6M; GAAP EPS $0.31 vs $0.49 YoY
Organic revenue grew 4% to $271.6M; reported revenue up 1%.
Bio-Techne appoints Shane Bohnen as SVP, General Counsel; Brenda Furlow retires March 3, 2023
Shane Bohnen, previously Associate General Counsel since 2019, becomes Senior VP, General Counsel effective March 3, 2023.
Bio-Techne Q1 FY2023 revenue up 7% organic, GAAP EPS $2.21, declares 4-for-1 stock split
Total revenue $269.7M, up 5% reported / 7% organic YoY.
Bio-Techne enters $1B revolving credit facility; draws $350M to repay prior debt
New $1B revolving credit facility, expandable by $400M, matures August 31, 2027.
Bio-Techne CEO Chuck Kummeth plans to retire by June 30, 2024; board begins successor search
Revenue grew from $311M in FY2013 to $1.1B in FY2022 (CAGR >15%); employees grew from 800 to 3,000+.
Bio-Techne announces Q4 FY2022 earnings and quarterly cash dividend
Results for fiscal fourth quarter ended June 30, 2022; specific figures not available in provided text.
Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14
Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.
Bio-Techne adopts Fourth Amended and Restated Bylaws with new shareholder meeting procedures
Uncontested director elections changed to majority of votes cast, consistent with amended articles.
Bio-Techne Q2 FY2022: GAAP EPS $1.94, adj EPS $1.88; rev $269.3M; $0.32 dividend, $400M buyback
Organic revenue +17% to $269.3M; Protein Sciences organic growth 19% with ProteinSimple up 27% and GMP Proteins >180%.
Bio-Techne appoints Will Geist President, Protein Sciences Segment, succeeding retiring Dave Eansor
Geist, former COO of Quanterix and former VP/GM at Thermo Fisher, appointed effective Jan 3, 2022.
Bio-Techne Q1 FY2022 revenue $257.7M, organic growth 21%; adjusted EPS $1.83 vs $1.43
Q1 FY2022 revenue $257.7M, organic growth 21% (reported 26%).
Bio-Techne annual meeting: say-on-pay passes with 55.3% support; all directors elected
Say-on-pay vote: 18,728,833 for, 15,113,930 against (55.3% approval excluding broker non-votes).
Bio-Techne Q4 FY2021 revenue up 47% to $259M; adjusted EPS $1.87 vs $1.00 YoY
Q4 organic revenue rose 39% to $259.0M; GAAP EPS $0.37, adjusted EPS $1.87 (vs $1.00 prior year).
On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.
On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.
On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.
Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company.
Mr. Kummeth will also retire from the Board of Directors on such date.
Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
Mr. Bohnen succeeds Brenda Furlow, who has announced her intention to retire on March 3, 2023.
appointed Mr. Shane Bohnen, age 48, as an executive officer of the Company in the position of Senior Vice President, General Counsel and Corporate Secretary, effective March 3, 2023.
On August 4, 2022, Bio-Techne Corporation (the “Company”) announced Chuck Kummeth’s plan to retire from his position as Chief Executive Officer effective June 30, 2024
Max materiality 1.00 · Median 0.65 · Most common event earnings